AR102217A1 - Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii - Google Patents
Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo iiInfo
- Publication number
- AR102217A1 AR102217A1 ARP150103256A ARP150103256A AR102217A1 AR 102217 A1 AR102217 A1 AR 102217A1 AR P150103256 A ARP150103256 A AR P150103256A AR P150103256 A ARP150103256 A AR P150103256A AR 102217 A1 AR102217 A1 AR 102217A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- ylmethyl
- hydrogen
- hydroxy
- cycloalkyl
- Prior art date
Links
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 title abstract 2
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- -1 methylacetylenyl Chemical group 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- QJQYPZZUKLQGGT-UHFFFAOYSA-N methyl hypobromite Chemical group COBr QJQYPZZUKLQGGT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen compuestos, composiciones y métodos para tratar trastornos que se afectan por la modulación del receptor GPR40. Reivindicación 1: Un compuesto de la fórmula (1), en donde: el anillo W es fenilo o piridilo; A es -CH₂O- u -OCH₂-; Z es CH o N; R⁶ es hidrógeno; R¹ se selecciona de hidrógeno o metilacetilenilo; o R¹ y R⁶ se toman juntos para formar un 3-hidrociclobutilo espirofusionado o un 3-oxociclobutilo ó espirofusionado; R² se selecciona de hidrógeno o metilo; R³ es hidrógeno, cloro, o un sustituyente seleccionado del grupo que consiste en alquilo C₁₋₃, hidroxi, 1,1-dioxotian-4-ilo, 1,1-dióxido-3,6-dihidro-2H-tiopiran-4-ilo, 1,1-dioxo-1,4-tiazinano-4-ilcarbonilo, alquilsulfonilo C₁₋₃, alquilsulfonilamino C₁₋₃, 1,1-dióxido-1-tia-6-azaespiro[3.3]heptan-6-ilo, piperidin-4-ilo, piperidin-4-ilmetilo, y -OR⁴; en donde R⁴ es: i) alquilo C₁₋₈ opcionalmente independientemente sustituido con uno o dos alcoxi C₁₋₃ o sustituyentes hidroxi; ii) cicloalquilo C₃₋₇; iii) 4-hidroxi-1,1-dioxo-tian-4-ilmetilo; iv) 1,1-dioxotian-4-ilo; v) 1,1-dioxidotetrahidro-2H-tiopiran-4-ilmetilo; vi) tetrahidro-2H-piran-4-ilo; vii) alquilsulfonilpropilo C₁₋₃; viii) 2-(1-hidroxiciclopropil)etilo; ix) 3-metiloxetan-3-il-metilo; x) (3-metil-1,1-dioxidotietan-3-il)metilo; xi) (1-cicloalquil C₃₋₆-1-ol)metilo; xii) 4-hidroxi-tetrahidropiran-4-ilmetilo; xiii) 2-(cicloalquil C₃₋₇)-2-hidroxietilo; xiv) tetrahidro-2H-piran-4-ilmetilo; xv) tetrahidrofuran-3-ilo; R⁵ es metilo, metoxi, bromo, cloro, alcoxi C₁₋₆-alcoxilo C₁₋₆, alquilsulfonilo C₁₋₆, o trifluorometilo; o un enantiómero, diastereómero, o formas de sal farmacéuticamente aceptable de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061330P | 2014-10-08 | 2014-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102217A1 true AR102217A1 (es) | 2017-02-15 |
Family
ID=54347869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103256A AR102217A1 (es) | 2014-10-08 | 2015-10-08 | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9790198B2 (es) |
| EP (1) | EP3204361A1 (es) |
| JP (1) | JP2017530986A (es) |
| KR (1) | KR20170063937A (es) |
| CN (1) | CN107001281A (es) |
| AR (1) | AR102217A1 (es) |
| AU (1) | AU2015330924A1 (es) |
| BR (1) | BR112017007014A2 (es) |
| CA (1) | CA2962955A1 (es) |
| CL (1) | CL2017000818A1 (es) |
| CO (1) | CO2017004074A2 (es) |
| EA (1) | EA201790800A1 (es) |
| IL (1) | IL251378A0 (es) |
| MA (1) | MA41041A (es) |
| MX (1) | MX2017004645A (es) |
| PH (1) | PH12017500653A1 (es) |
| SG (1) | SG11201702683VA (es) |
| TW (1) | TW201629033A (es) |
| UY (1) | UY36348A (es) |
| WO (1) | WO2016057731A1 (es) |
| ZA (1) | ZA201703112B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
| KR20180026459A (ko) | 2015-06-18 | 2018-03-12 | 세파론, 인코포레이티드 | 1,4-치환된 피페리딘 유도체 |
| US10106553B2 (en) | 2016-04-11 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
| US10195178B2 (en) | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
| EP3281937A1 (en) * | 2016-08-09 | 2018-02-14 | Dompé farmaceutici S.p.A. | Sulfonamides as gpr40- and gpr120-agonists |
| CN110590767B (zh) * | 2019-08-29 | 2021-10-08 | 南方科技大学 | 一种合成amg837的方法 |
| EP4041722A4 (en) | 2019-10-07 | 2023-12-13 | Kallyope, Inc. | GPR119 AGONISTS |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| CN115925678B (zh) * | 2022-11-28 | 2024-06-21 | 郑州海阔光电材料有限公司 | 一种3-（4-溴苯基）苯并噻吩的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0109107A (pt) | 2000-03-09 | 2002-12-03 | Aventis Pharma Gmbh | Usos terapêuticos de mediadores ppar |
| EP1559422B1 (en) * | 2002-11-08 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US7384965B2 (en) | 2003-01-06 | 2008-06-10 | Eli Lilly And Company | Fused heterocyclic derivatives as PPAR modulators |
| WO2005040102A2 (en) | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd. | Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them |
| US7816367B2 (en) | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
-
2015
- 2015-10-06 TW TW104132761A patent/TW201629033A/zh unknown
- 2015-10-07 MA MA041041A patent/MA41041A/fr unknown
- 2015-10-08 AU AU2015330924A patent/AU2015330924A1/en not_active Abandoned
- 2015-10-08 CA CA2962955A patent/CA2962955A1/en not_active Abandoned
- 2015-10-08 WO PCT/US2015/054581 patent/WO2016057731A1/en not_active Ceased
- 2015-10-08 UY UY0001036348A patent/UY36348A/es unknown
- 2015-10-08 MX MX2017004645A patent/MX2017004645A/es unknown
- 2015-10-08 AR ARP150103256A patent/AR102217A1/es unknown
- 2015-10-08 SG SG11201702683VA patent/SG11201702683VA/en unknown
- 2015-10-08 CN CN201580066945.6A patent/CN107001281A/zh active Pending
- 2015-10-08 BR BR112017007014A patent/BR112017007014A2/pt not_active Application Discontinuation
- 2015-10-08 EP EP15784860.7A patent/EP3204361A1/en not_active Withdrawn
- 2015-10-08 JP JP2017518944A patent/JP2017530986A/ja active Pending
- 2015-10-08 EA EA201790800A patent/EA201790800A1/ru unknown
- 2015-10-08 US US14/877,972 patent/US9790198B2/en not_active Expired - Fee Related
- 2015-10-08 KR KR1020177012143A patent/KR20170063937A/ko not_active Withdrawn
-
2017
- 2017-03-26 IL IL251378A patent/IL251378A0/en unknown
- 2017-04-04 CL CL2017000818A patent/CL2017000818A1/es unknown
- 2017-04-07 PH PH12017500653A patent/PH12017500653A1/en unknown
- 2017-04-26 CO CONC2017/0004074A patent/CO2017004074A2/es unknown
- 2017-05-05 ZA ZA2017/03112A patent/ZA201703112B/en unknown
- 2017-09-07 US US15/697,867 patent/US10131648B2/en active Active
-
2018
- 2018-10-30 US US16/174,378 patent/US10662170B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201702683VA (en) | 2017-04-27 |
| US20170362196A1 (en) | 2017-12-21 |
| CL2017000818A1 (es) | 2017-11-03 |
| EP3204361A1 (en) | 2017-08-16 |
| US20160102071A1 (en) | 2016-04-14 |
| US20190062300A1 (en) | 2019-02-28 |
| US10131648B2 (en) | 2018-11-20 |
| US10662170B2 (en) | 2020-05-26 |
| BR112017007014A2 (pt) | 2017-12-26 |
| TW201629033A (zh) | 2016-08-16 |
| MX2017004645A (es) | 2017-10-16 |
| CO2017004074A2 (es) | 2017-07-19 |
| CN107001281A (zh) | 2017-08-01 |
| MA41041A (fr) | 2017-08-15 |
| AU2015330924A1 (en) | 2017-04-13 |
| IL251378A0 (en) | 2017-05-29 |
| UY36348A (es) | 2016-06-30 |
| KR20170063937A (ko) | 2017-06-08 |
| US9790198B2 (en) | 2017-10-17 |
| PH12017500653A1 (en) | 2017-10-02 |
| JP2017530986A (ja) | 2017-10-19 |
| EA201790800A1 (ru) | 2017-10-31 |
| WO2016057731A1 (en) | 2016-04-14 |
| CA2962955A1 (en) | 2016-04-14 |
| ZA201703112B (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR100137A1 (es) | Compuestos 4-amino-imidazoquinolina | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR092503A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
| PE20170206A1 (es) | Inhibidores espirociclicos sustituidos de la autotaxina | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR080703A1 (es) | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |